Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Verapamil · 4 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Verapamil Hydrochloride Extended-Release Capsules, 300 mg |
| 2 | ACTIVE_COMPARATOR | Verelan® PM Extended-Release Capsules, 300 mg |
| Name | Type | Description |
|---|---|---|
| Verapamil Hydrochloride Extended-Release Capsules, 300 mg | DRUG | 300mg, single dose fasting |
| Verelan® PM Extended-Release Capsules, 300 mg | DRUG | 300mg, single dose fasting |
| Verapamil HCL Extended-Release Capsules 300 mg | DRUG | 300mg, single dose fasting |
| Verelan® PM Extended-Release Capsules 300 mg | DRUG | 300mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have a negative serum (β HCG) pregnancy test performed within 21 days prior to the start of the study and on the evening prior to each dose administrat...
Verapamil is a small molecule drug developed by Viatris Inc. under the ticker VTRS. It is being studied in Phase 1 clinical development. The specific indication being investigated is undisclosed. Verapamil is also known as Verapamil Hydrochloride Extended-Release Capsules, 300 mg, or Verapamil HCL Extended-Release Capsules 300 mg.
Verapamil targets CACNA1C, CACNA1S, CACNA1D, and CACNA1F. It is classified as a blocker. These calcium channel targets are involved in regulating calcium ion flow across cell membranes. By blocking these channels, Verapamil modulates calcium-dependent signaling processes.
Verapamil is developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the company responsible for the clinical development of this extended-release capsule formulation of Verapamil.
Verapamil is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for the undisclosed indication being studied. The Phase 1 program includes four completed trials with a total enrollment of 144 participants.
Verapamil has been studied in four completed Phase 1 trials: NCT00649805, NCT00648401, NCT00648050, and NCT00647673. These trials evaluated Verapamil HCl Extended-Release Capsules 300 mg compared to Verelan PM Extended-Release Capsules 300 mg in healthy volunteers under fasting and food conditions in the United States.
Yes, Verapamil is also known as Verapamil Hydrochloride Extended-Release Capsules, 300 mg, or Verapamil HCL Extended-Release Capsules 300 mg. These names refer to the same 300 mg extended-release capsule formulation developed by Viatris Inc. under the ticker VTRS.